MTOR and breast cancer: Drugs including celecoxib (COX-2 inhibitor) and rapamycin (mTOR inhibitor) were co-loaded into the nanocapsules to inhibit the proliferation of MCF-7 and MDA-MB-231 breast cancer cells, signifying the enhanced cytotoxicity of the nanocapsules against breast cancer cells.